Presentation is loading. Please wait.

Presentation is loading. Please wait.

Erratum Journal of Thoracic Oncology

Published byJacob Mills Modified over 5 years ago

Similar presentations

Presentation on theme: "Erratum Journal of Thoracic Oncology"— Presentation transcript:

1 Erratum Journal of Thoracic Oncology
Journal of Thoracic Oncology  Volume 3, Issue 2, Pages (February 2008) DOI: /JTO.0b013e31815f63f3 Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Survival According to Epidermal Growth Factor Receptor Genotype. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e31815f63f3) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 4 Survival by Epidermal Growth Factor Receptor (EGFR) protein expression and treatment for patients in BR.21 with no expression of EGFR (a) and with expression of EGFR (b), and for patients in ISEL with no expression of EGFR (c), and with expression if EGFR (d).4,9 Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e31815f63f3) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 5 Survival by Epidermal Growth Factor Receptor (EGFR) gene copy number and treatment for patients in BR.21 with EGFR fluorescence in situ hybridization (FISH)-negative disease (a) and EGFR FISH-positive disease (b), and for patients in ISEL with EGFR FISH-negative disease (c) and EGFR FISH-positive disease (d).4,9 Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e31815f63f3) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Erratum Journal of Thoracic Oncology"

Similar presentations

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages 1862-1863.

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Is Cytology Reliable for Epidermal Growth Factor Receptor Gene Evaluation in Non- small Cell Lung Cancer?  Cecilia Bozzetti, PhD, Marcello Tiseo, MD, Costanza.

Is Cytology Reliable for Epidermal Growth Factor Receptor Gene Evaluation in Non- small Cell Lung Cancer?  Cecilia Bozzetti, PhD, Marcello Tiseo, MD, Costanza.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
EGFR Gene Alterations in a Norwegian Cohort of Lung Cancer Patients Selected for Surgery  Åslaug Helland, MD, PhD, Hege Marian Skaug, MSc, Lilach Kleinberg,

EGFR Gene Alterations in a Norwegian Cohort of Lung Cancer Patients Selected for Surgery  Åslaug Helland, MD, PhD, Hege Marian Skaug, MSc, Lilach Kleinberg,
Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.
EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies  Sandra Salvi, PhD, Serena Varesano, PhD, Simona.

EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies  Sandra Salvi, PhD, Serena Varesano, PhD, Simona.
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.
Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,
Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,
The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

Similar presentations

Ads by Google